Alexandre Reuben, Ph.D.

Peer-Reviewed Articles

1. Zhu B, Aminu M, Chen P, Li JR, Dong C, Li C, Tian Y, Lu SW, Chen H, Ma C, Hu X, Ye J, Liu AY, Huang B, Rojas FR, Roger PCE, Shi O, Nilsson MB, Poteete A, Khan KB, Lu W, Solis Soto LM, Fujimoto J, Haymaker C, Wistuba II, Wei Z, Wang L, Gibbons DL, Chen K, Reuben A, Schenke JM, Heymach JV, Cheng C, Wu J, Zhang J. Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure. Adv Sci (Weinh):e12597, 2026. e-Pub 2026. PMID: 41580978.
2. Fukumura K, Jiang P, Yeboa DN, Raghavendra AS, Gubbiotti MA, Andersen CR, Ferguson SD, Duose DY, Kudo Y, Arun B, Reuben A, Huse JT, Ibrahim NK. Ionizing radiation engages prognostically significant cellular immunity programs in the brain metastasis microenvironment. e-Pub 2026.
3. Maher M, Prevost T, Duose D, Lan J, Haymaker C, Reuben A, Wistuba I, Stanford M, Oliva-Ramirez J, Tomczak K, Medina Rosales M, Tsao A, Mehran R, Altan M, Luthra R. Analytical validation and cross-platform analysis of the oncomine TCR pan-clonality assay for T-Cell receptor profiling 298-299:S6. e-Pub 2026.
4. Sherry AD, Siddiqui BA, Haymaker C, Fellman BM, Medina-Rosales MN, Bathala TK, Wang S, Liu S, Seo A, Hara K, Lu H, Troncoso P, Chun SG, Ha CS, Mayo LL, Mok H, Park RJ, Chapin BF, Phillips RM, Deek MP, Kovitz CA, Aparicio A, Zurita AJ, Pilie PG, Cohen L, Choi SL, Reuben A, Tran PT, Corn PG, Subudhi SK, Tang C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol, 2025. e-Pub 2025. PMID: 40750497.
5. Cote F, Prairie E, Sierra EM, Quiniou C, Habelrih T, Xu W, Ferri B, Hou X, Lahaie I, Cote N, Loiselle SE, Gobeil L, Sawaya K, Faucher A, Beaulieu A, Delisle S, Simard MP, Mohammad Nezhady MA, Laplante V, Reuben A, Kalaidji SM, Bajon E, Cagnone G, Leimert KB, Gauchat JF, Gaudreau L, Robertson S, Lubell WD, Olson DM, Chemtob S. A novel modulator of IL-6R prevents inflammation-induced preterm birth and improves newborn outcome. EMBO Mol Med, 2025. e-Pub 2025. PMID: 40610814.
6. Hallaert, P, Roman, John W, Baker, M, Hill, N, Marte, J, Gulley, J, Logemann, N, Hudgens, CW, Reuben, A, Brownell, I. Spontaneous tumor regression and immunotherapy response demonstrate clonal T-cell expansion in Merkel cell carcinoma. NPJ Precis Oncol 9(1):212, 2025. e-Pub 2025. PMID: 40594889.
7. Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran H, Parra E, Byers L, Reuben A, Federico L, Bernatchez Ch, Wang J, Antonoff MB, Vaporciyan A, Swisher S, Cascone T, Wistuba I, Heymach JV, Gibbons D, Zhang J, McGrail D, Seposi B, Haymaker C. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer. e-Pub 2025. PMID: 40555561.
8. Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
9. Browning MHEM, Shan J, Alexeeff SE, Becker D, Greenberg JA, Kuo M, McAnirlin O, Reuben A, Wolf KL, Astell Burt T, Van Den Eeden SK. Moving to greener neighborhoods and healthcare costs in Northern California. Environ Epidemiol 9(3):e392, 2025. e-Pub 2025. PMID: 40356618.
10. Tujios SR, Rule JA, Sussman N, Rakela JL, Ganger D, Bass N, Reuben A, Stravitz RT, Kleiner D, Wang H, Choi EK, Peng L, Yeh M, Hatfield B, Yang GY, Gill R, Fontana RJ, Lee WM. Clinical and pathological spectrum of disease severity among patients with acute liver failure (ALF) undergoing deceased donor liver transplantation. Liver Transpl, 2025. e-Pub 2025. PMID: 40341552.
11. Hu, J, Jin, M, Feng, W, Nassif-Rausseo, B, Reuben, A, Ma, CH, Lizee, GA, Li, F. Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer. Vaccines 13(5), 2025. e-Pub 2025. PMID: 40432130.
12. McFarland MJ, Reuben A, Hauer M. Contribution of childhood lead exposure to psychopathology in the US population over the past 75 years. J Child Psychol Psychiatry 66(5):659-666, 2025. e-Pub 2025. PMID: 39628272.
13. Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L, Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S, Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D, Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A, Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE, Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D, Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D, Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker H, Barone F, Chiocca EA. A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. Neuro Oncol, 2025. e-Pub 2025. PMID: 40120123.
14. Reddy, JP, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Cohen, L, Smith, B, Ramirez, DL, Shaitelman, SF, Chun, SG, Medina-Rosales, M, Teshome, M, Brewster, A, Barcenas, CH, Reuben, A, Ghia, AJ, Ludmir, EB, Weed, D, Shah, SJ, Mitchell, MP, Woodward, W, Gomez, D, Tang, C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND). International Journal of Radiation Oncology Biology Physics 121(4):885-893, 2025. e-Pub 2025. PMID: 39486645.
15. Barrett-Young A, Reuben A, Caspi A, Cheyne K, Ireland D, Kokaua J, Ramrakha S, Tham YC, Theodore R, Wilson G, Wong TY, Moffitt T. Measures of retinal health successfully capture risk for Alzheimer's disease and related dementias at midlife. J Alzheimers Dis:13872877251321114, 2025. e-Pub 2025. PMID: 40033783.
16. Dixit, DD, Singampalli, KL, Niyogi, AS, Montoya, A, Reuben, A, Lillehoj, PB. Rapid laser ablation-based fabrication of high-density polymer microwell arrays for high-throughput cellular studies. Lab on a Chip 25(7):1813-1822, 2025. e-Pub 2025. PMID: 40040352.
17. Johnson, FM, O’Hara, MP, Yapindi, L, Jiang, P, Tran, HT, Reuben, A, Xiao, W, Gillison, M, Sun, X, Khalaf, A, Lee, JJ, Sastry, JK, Ghosh, S. Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research 31(3):479-490, 2025. e-Pub 2025. PMID: 39589337.
18. Altan, M, Li, R, Li, Z, Chen, R, Sheshadri, A, Tran, HT, Little, L, Baguley, J, Sinson, JC, Vokes, N, Gandhi, S, Antonoff, MB, Swisher, SG, Lizee, GA, Reuben, A, Heymach, JV, Zhang, J. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. Journal for immunotherapy of cancer 12(12), 2024. e-Pub 2024. PMID: 39721752.
19. Jin, Y, Wu, Y, Reuben, A, Zhu, L, Gay, CM, Wu, Q, Zhou, X, Mo, H, Zheng, Q, Ren, J, Fang, Z, Peng, T, Wang, N, Ma, L, Fan, Y, Song, H, Zhang, J, Chen, M. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discovery 10(1), 2024. e-Pub 2024. PMID: 39231924.
20. Ludmir, EB, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Medina-Rosales, M, Reuben, A, Holliday, EB, Smith, GL, Noticewala, SS, Nicholas, S, Price, TR, Martin, RM, Perles, LA, Lee, SS, Lee, MS, Smaglo, BG, Huey, RW, Willis, JA, Zhao, D, Cohen, L, Taniguchi, C, Koay, EJ, Katz, MH, Wolff, RA, Das, P, Pant, S, Koong, A, Tang, C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND). Journal of Clinical Oncology 42(32):3795-3805, 2024. e-Pub 2024. PMID: 39102622.
21. Li, Y, Ji, L, Zhang, Y, Zhang, J, Reuben, A, Zeng, H, Huang, Q, Wei, Q, Tan, S, Xia, X, Li, W, Zhang, J, Tian, P. The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer. MedComm 5(6), 2024. e-Pub 2024. PMID: 38840771.
22. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
23. Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez F, Heeke S, Moreira A, Solis L, Haymaker C, Velcheti V, Sterman D, Pass H, Cheng Ch, Lee J, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su S, Fukuoka J, Antonoff M, Gerber D, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Apira A, Futreal A, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. e-Pub 2024. PMID: 38798564.
24. Bolivar AM, Duzagac F, Deng N, Reyes-Uribe L, Chang K, Wu W, Bowen CM, Taggart MW, Thirumurthi S, Lynch PM, You YN, Rodriguez-Pascual J, Lipkin SM, Kopetz S, Scheet P, Lizee GA, Reuben A, Sinha KM, Vilar E. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention. Gastroenterology 166(5):787-801.e11, 2024. e-Pub 2024. PMID: 38244726.
25. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman R, Ramirez D, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy. Clin Cancer Res. e-Pub 2024. PMID: 38629963.
26. Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, Bai H, Duan J, Wan R, Zhao J, Bai J, Xia X, Yi X, Cheng C, Wang J, Wang Z. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun 15(1):1199, 2024. e-Pub 2024. PMID: 38331912.
27. Han Y, Yang Y, Tian Y, Fattah FJ, von Itzstein MS, Hu Y, Zhang M, Kang X, Yang DM, Liu J, Xue Y, Liang C, Raman I, Zhu C, Xiao O, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Pan K, Wu F, Gibbons D, Wang X, Yee C, Huang J, Reuben A, Cheng C, Zhang J, Gerber DE, Wang T. pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding. bioRxiv, 2023. e-Pub 2023. PMID: 38105939.
28. Das P, Peterson CB, Ni Y, Reuben A, Zhang J, Zhang J, Do KA, Baladandayuthapani V. Bayesian hierarchical quantile regression with application to characterizing the immune architecture of lung cancer. Biometrics 79(3):2474-2488, 2023. e-Pub 2023. PMID: 36239535.
29. Ying L, Zhang C, Reuben A, Tian Y, Jin J, Wang C, Bai J, Liu X, Fang J, Feng T, Xu C, Zhu R, Huang M, Lyu Y, Lu T, Pan X, Zhang J, Su D. Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma. iScience 26(9):107732, 2023. e-Pub 2023. PMID: 37694148.
30. Huang J, Zhao G, Peng Q, Yi X, Ji L, Li J, Li P, Guan Y, Ge J, Chen L, Chen R, Hu X, Lee WC, Reuben A, Futreal PA, Xia X, Ma J, Zhang J, Chen Z. Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell-receptor sequencing. Mol Oncol 17(8):1531-1544, 2023. e-Pub 2023. PMID: 36703611.
31. Li C, Zhang B, Schaafsma E, Reuben A, Wang L, Turk MJ, Zhang J, Cheng C. TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs. Cell Rep Med 4(7):101121, 2023. e-Pub 2023. PMID: 37467716.
32. Li R, Altan M, Reuben A, Lin R, Heymach JV, Tran H, Chen R, Little L, Hubert S, Zhang J, Li Z. A novel statistical method for decontaminating T-cell receptor sequencing data. Brief Bioinform 24(4), 2023. e-Pub 2023. PMID: 37337757.
33. Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell 41(7):1363-1380.e7, 2023. e-Pub 2023. PMID: 37327788.
34. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
35. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
36. Frank ML, Lu K, Erdogan C, Han Y, Hu J, Wang T, Heymach JV, Zhang J, Reuben A. T cell receptor repertoire sequencing in the era of cancer immunotherapy. Clin Cancer Res 29(6):994-1008, 2023. e-Pub 2023. PMID: 36413126.
37. Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1):100028, 2023. e-Pub 2023. PMID: 36788067.
38. Chen, R, Li, J, Fujimoto, J, Hong, L, Hu, X, Quek, YK, Tang, M, Mitra, A, Behrens, MC, Chow, CW, Jiang, P, Little, L, Gumbs, C, Song, X, Zhang, J, Tan, D, Heymach, JV, Wistuba, II, Futreal, A, Gibbons, DL, Byers, LA, Zhang, J, Reuben, A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research 41(1), 2022. e-Pub 2022. PMID: 35546239.
39. Lu T, Park S, Han Y, Wang Y, Hubert SM, Futreal PA, Wistuba I, Heymach JV, Reuben A, Zhang J, Wang T. Netie: inferring the evolution of neoantigen-T cell interactions in tumors. Nat Methods 19(11):1480-1489, 2022. e-Pub 2022. PMID: 36303017.
40. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28. e-Pub 2022. PMID: 35973335.
41. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
42. Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. Cancer Discov. e-Pub 2022. PMID: 35849783.
43. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow C, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal P, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022. e-Pub 2022.
44. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
45. Colbert LE, Alam MBE, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. e-Pub 2022. PMID: 35045973.
46. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
47. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
48. Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, Bernatchez C, Heymach JV, Gibbons DL, Wang J, Xu L, Reuben A, Wang T. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell 3(10):864-875, 2021. e-Pub 2021. PMID: 36003885.
49. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol. e-Pub 2021. PMID: 34653632.
50. Chen K, Bai J, Reuben A, Zhao H, Kang G, Zhang C, Qi Q, Xu Y, Hubert S, Chang L, Guan Y, Feng L, Zhang K, Zhang K, Yi X, Xia X, Cheng S, Yang F, Zhang J, Wang J. Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. Am J Respir Crit Care Med. e-Pub 2021. PMID: 34473939.
51. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
52. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. e-Pub 2021. PMID: 34239137.
53. Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
54. Qin SS, Han BJ, Williams A, Jackson KM, Jewell R, Chacon AC, Lord EM, Linehan DC, Kim M, Reuben A, Gerber SA, Prieto PA. Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model. Cancers (Basel) 13(10), 2021. e-Pub 2021. PMID: 34064795.
55. Abbas HA, Reville PK, Jiang X, Yang H, Reuben A, Im JS, Little L, Sinson JC, Chen K, Futreal A, Garcia-Manero G. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Front Immunol 12:659625, 2021. e-Pub 2021. PMID: 33912187.
56. Chiou SH, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, Wilhelmy J, McSween AM, Yang X, Nishimiya D, Sinha R, Nabet BY, Wang C, Shrager JB, Berry MF, Backhus L, Lui NS, Wakelee HA, Neal JW, Padda SK, Berry GJ, Delaidelli A, Sorensen PH, Sotillo E, Tran P, Benson JA, Richards R, Labanieh L, Klysz DD, Louis DM, Feldman SA, Diehn M, Weissman IL, Zhang J, Wistuba II, Futreal PA, Heymach JV, Garcia KC, Mackall CL, Davis MM. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity 54(3):586-602.e8, 2021. e-Pub 2021. PMID: 33691136.
57. Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, Bussi Y, Rotkopf R, Levy R, Benedek G, Trabish S, Dadosh T, Levin-Zaidman S, Geller LT, Wang K, Greenberg P, Yagel G, Peri A, Fuks G, Bhardwaj N, Reuben A, Hermida L, Johnson SB, Galloway-Peña JR, Shropshire WC, Bernatchez C, Haymaker C, Arora R, Roitman L, Eilam R, Weinberger A, Lotan-Pompan M, Lotem M, Admon A, Levin Y, Lawley TD, Adams DJ, Levesque MP, Besser MJ, Schachter J, Golani O, Segal E, Geva-Zatorsky N, Ruppin E, Kvistborg P, Peterson SN, Wargo JA, Straussman R, Samuels Y. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. e-Pub 2021. PMID: 33731925.
58. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. e-Pub 2021. PMID: 33603241.
59. Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
60. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology 10(1):1992880, 2021. e-Pub 2021. PMID: 34777916.
61. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporiciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol. e-Pub 2020. PMID: 33388477.
62. Qin Y, Bollin K, de Macedo MP, Carapeto F, Kim KB, Roszik J, Wani KM, Reuben A, Reddy ST, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Lazar AJ, Hwu P, Patel SP. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33203661.
63. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
64. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara H, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer. J Thorac Oncol. e-Pub 2020. PMID: 33096269.
65. Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. e-Pub 2020. PMID: 32917656.
66. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
67. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
68. Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J. Evolution of genomic and T cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. Clin Cancer Res. e-Pub 2020. PMID: 32816946.
69. Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
70. Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med. e-Pub 2020. PMID: 32730093.
71. Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T. Multifactorial deep learning reveals pan-cancer genomic tumor clusters with distinct immunogenomic landscape and response to immunotherapy. Clin Cancer Res 26(12):2908-2920, 2020. e-Pub 2020. PMID: 31911545.
72. Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T CELL REPERTOIRE IN COMBINATION WITH T CELL DENSITY PREDICTS CLINICAL OUTCOMES IN PATIENTS WITH MERKEL CELL CARCINOMA. J Invest Dermatol. e-Pub 2020. PMID: 32304704.
73. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
74. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32350118.
75. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
76. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
77. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
78. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
79. Keung EZ, Burgess M, Salazar R, Parra Cuentas E, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno S, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke DK, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. e-Pub 2020. PMID: 31900276.
80. Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 25(21):6429-6442, 2019. e-Pub 2019. PMID: 31439581.
81. Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A 116(45):22699-22709, 2019. e-Pub 2019. PMID: 31636208.
82. Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial. Int J Radiat Oncol Biol Phys. e-Pub 2019. PMID: 31678224.
83. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra-Cuentas ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer. Ann Oncol. e-Pub 2019. PMID: 31282941.
84. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 10(1):2978, 2019. e-Pub 2019. PMID: 31278276.
85. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
86. Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res 7(6):1025-1035, 2019. e-Pub 2019. PMID: 31043414.
87. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
88. Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. e-Pub 2019. PMID: 30883858.
89. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 176(1-2):404, 2019. e-Pub 2019. PMID: 30633907.
90. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. e-Pub 2018. PMID: 30297909.
91. Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. Cancer Discov. e-Pub 2018. PMID: 30209080.
92. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
93. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
94. Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology 7(5):e1423172, 2018. e-Pub 2018. PMID: 29721378.
95. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
96. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156-1160, 2017. e-Pub 2017. PMID: 28912244.
97. Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med 214(6):1691-1710, 2017. e-Pub 2017. PMID: 28450382.
98. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
99. Cogdill AP, Prieto PA, Reuben A, Wargo JA. Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. Clin Cancer Res 23(2):327-329, 2017. e-Pub 2017. PMID: 27836861.
100. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
101. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6(12):e1361097, 2017. e-Pub 2017. PMID: 29209563.
102. Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6(6):e1321187, 2017. e-Pub 2017. PMID: 28680759.
103. Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res 22(22):5553-5563, 2016. e-Pub 2016. PMID: 27166398.
104. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
105. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
106. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
107. Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA. Working with Human Tissues for Translational Cancer Research. J Vis Exp(105), 2015. e-Pub 2015. PMID: 26649748.
108. Reuben A, Austin-Breneman J, Wargo JA, Cooper ZA. Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Ann Transl Med 3(18):272, 2015. e-Pub 2015. PMID: 26605318.
109. Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res 21(14):3102-4, 2015. e-Pub 2015. PMID: 26025561.
110. Reuben A, Godin-Ethier J, Santos MM, Lapointe R. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells. Mol Immunol 65(2):259-66, 2015. e-Pub 2015. PMID: 25700349.
111. Reuben A, Amaria RN, Cooper ZA, Wargo JA. RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. J Pigment Disord 1(5), 2014. e-Pub 2014. PMID: 29250602.
112. Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology 3(9):e954956, 2014. e-Pub 2014. PMID: 25941608.
113. Reuben A, Phénix M, Santos MM, Lapointe R. The WT hemochromatosis protein HFE inhibits CD8+ T-lymphocyte activation. Eur J Immunol 44(6):1604-14, 2014. e-Pub 2014. PMID: 24643698.
114. Forget MA, Huon Y, Reuben A, Grange C, Liberman M, Martin J, Mes-Masson AM, Arbour N, Lapointe R. Stimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype. PLoS One 7(7):e41074, 2012. e-Pub 2012. PMID: 22859966.
115. Forget MA, Reuben A, Turcotte S, Martin J, Lapointe R. Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancer. Cancer Immunol Immunother 60(8):1119-25, 2011. e-Pub 2011. PMID: 21681374.
116. Bontekoe E, Zhang M, Jiang P, Montoya A, Shulga Y, Slone J, Paul E, Polera C, Forward S, Nassif Rausseo B, Assita E, Xing C, Molkentine D, Morris B, Polic I, Roszik J, Salgado R, Vaishnavi A, Deniger D, Tran H, Gibbons D, Vaporciyan A, Gillison M, Wistuba I, Kavroki L, Zhang J, Lizzee G, Yee C, Hwu P, Kwok S, Jaeger A, Heymach J, Reuben A. FOXM1 is prevalent in lung cancer and targetable via T cell receptor engineering. Cancer Immunology Research.

Review Articles

1. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell 33(4):570-580, 2018. e-Pub 2018. PMID: 29634945.
2. Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol 9:946, 2018. e-Pub 2018. PMID: 29780391.
3. Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL. Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. Clin Lab Med 37(3):431-448, 2017. e-Pub 2017. PMID: 28802494.
4. Reuben A, Chung JW, Lapointe R, Santos MM. The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. Immun Inflamm Dis 5(3):218-232, 2017. e-Pub 2017. PMID: 28474781.
5. Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. Cancer 123(S11):2130-2142, 2017. e-Pub 2017. PMID: 28543700.
6. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31, 2016. e-Pub 2016. PMID: 27240055.
7. Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep 18(7):42, 2016. e-Pub 2016. PMID: 27215436.
8. Prieto PA, Reuben A, Cooper ZA, Wargo JA. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J 22(2):138-46, 2016. e-Pub 2016. PMID: 27111910.
9. Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 42(4):601-16, 2015. e-Pub 2015. PMID: 26320064.
10. Amaria RN, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther 4:79-89, 2015. e-Pub 2015. PMID: 27471714.
11. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 11(4):237-46, 2014. e-Pub 2014. PMID: 25610709.

Other Articles

1. Jin, Y, Wu, Y, Reuben, A, Zhu, L, Gay, CM, Wu, Q, Zhou, X, Mo, H, Zheng, Q, Ren, J, Fang, Z, Peng, T, Wang, N, Ma, L, Fan, Y, Song, H, Zhang, J, Chen, M Correction to. Cell Discovery 10(1), 2024. PMID: 39702462.

Abstracts

1. Park M, Hu X, Montegut L, Zhu B, Vokes N, Fujimoto J, Hong J, Hong L, Heeke S, Moreira A, Solis L, Haymaker C, Velcheti V, Sterman D, Pass H, Cheng C, Lee J, Wei Z, Wu J, Su D, Wang L, Davis M, Heymach J, Wistuba I, Dubinett S, Lippman S, Apira A, Samstein R, Mantovani A, Futreal A, Reuben A, Merad M, Zhang J. PP01.23/OA07.01: Myeloid IL-1 Signaling Drives The Precancer-to-Cancer Evolution of Human Pulmonary Nodules 21(1), 2026. e-Pub 2026.
2. Truong Do M, Zhu T, Yassouf M, lee R, Abadneh O, Tian Y, Rodriguez L, Gudikote J, Araujo H, Schmidt S, Wang J, Rojas Alvarez F, Solis Soto L, Negrao MV, Reuben A, Albacker L, Gibbons D, Zhang J, Heymach J, Skoulidis F. RBM10 loss promotes KRAS-mutant non-small cell lung cancer immune tolerance and PD-1 inhibitor resistance via a non-canonical STING/ NF-κB axis. e-Pub 2025.
3. Tian Y, Li J, Zhu B, Fradette J, Chen H, Wei Z, Ye J, Lu S, Liu A, Kundu S, Wu H, Miao S, Le X, Wang L, Wu J, Reuben A, Heymach J, Futreal A, Naota H, Cheng C, Gibbons D, Zhang J. Spatiotemporal Analysis Reveals tsMHC-I Downregulation-Induced Neutrophil Extracellular Traps as a Driver of Lung Adenocarcinoma Neoplastic Evolution. e-Pub 2025.
4. Deepak Dixit D, Jiang P, Reuben A, Lillehoj P. MICROWELL-PATTERNED MICROFLUIDIC DEVICE FOR RAPID IDENTIFICATION OF HIGH-AFFINITY ANTI-TUMOR T CELLS. e-Pub 2024.
5. Perez-Sandi IM, Zhang M, Nie H, Jiang P, Yee C, Lizee G, Heymach JV, Reuben A. T cell receptor engineering targeting FOXM1 for the treatment of lung cancer. 2023 Summer Experience(64), 2023. e-Pub 2023.
6. Barone F, Wen PY, Dualt C, Gonzalez-Kozlova E, Holmes T, Kim-Schulze S, Nie K, Argueta K, Fehr J, Pichavant MR, Del Valle DM, Gentles A, Gnjatic S, Ye X, Taing L, Geisberg J, Wistuba II, Haymaker C, Al-Atrash G, Luthra R, Duose DY, Zhang B, Lan J, Wang S, Reuben A, Jiang PP, Lopez L, Bell S, Manzanera AG, Caine A, Dwyer J, Lawler SE, Danda N, Desideri S, Nabors LB, Grossman S, Chiocca EA, Tak PP, Maecker HT. Multi-Omnic Analysis Data from Phase 1 Clinical Trial of CAN-2409 + Valacyclovir in combination with Nivolumab in High-Grade Glioma Demonstrates Systemic Activity after Local Delivered CAN-2409 Viral Immunotherapy, 2023. e-Pub 2023.
7. Hu Q, Frank ML, Gao Y, Ji L, Peng M, Chen C, Wang B, Hu Y, Wu Z, Li J, Shu L, He Q, Zhang Y, Xia X, Zhang J, Yi X, A R, Yu F. Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues. Oncoimmunology 12(1):2233399, 2023. e-Pub 2023. PMID: 37876834.
8. Duzagac F, Sinha K, Bolivar A, Deng N, Uribe LR, Reuben A, Vilar-Sanchez E. 28 Identification and functional validation of neoantigens-specific T-cell receptors in lynch syndrome. Journal for Immunotherapy of Cancer 10(2), 2022. e-Pub 2022.
9. Bolivar A, Vilar-Sanchez E, Sinha K, Uribe LR, Deng N, Duzagac F, Reuben A. 36 Analysis of T-cell receptor sequences identifies signatures associated with neoantigen exposure in peripheral blood of lynch syndrome patients. Journal of Immunotherapy of Cancer 10(2), 2022. e-Pub 2022.
10. Nassif EF, Keung EZ, Jiang P, Reuben A, Crosby S, Mathew G, Lazar A, Torres K, Wang WL, Guadagnolo A, Bishop A, Hunt KK, Bird J, Lewis V, Conley AP, Wargo JA, Somaiah N, Roland CL. 1493MO Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with …. Annals of Oncology 33:S1229-S1230, 2022. e-Pub 2022.
11. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li, J, Fujiomoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget M, McGrail DJ, Weissferdt A, Lin S, Lee Y, Suzuki E, Kovaks JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Herffernan TP, Negrao MV, Gibbons DL, team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non–Small-Cell Lung Cancer Data Set. JCO Clinical Cancer Informatics 6:e2200040, 2022. e-Pub 2022.
12. Ying L, Zhang C, Reuben A, Tian Y, Jin J, Wang C, Bai J, Fang J, Feng T, Xu C, Zhu R, Huang M, Yingqi L, Liu X, Lu T, Pan X, Zhang J, Su D. Spatial multiomics profiling reveals immune features in tumor-adjacent tissues associated with survival of stage I lung squamous cell carcinoma patients, 2022. e-Pub 2022.
13. Qian Y, Guijarro I, Galan-Cobo A, Dang M, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Skoulidis F, Wistuba I, Verma S, Merghoub T, Wang L, Wolchok J, Reuben A, Heymach J. MCT4 blockade reverses lactate-mediated immunosuppression in LKB1-deficient NSCLC. Cancer Research 82(12):2160-2160, 2022. e-Pub 2022.
14. Galan-Cobo A, Qian Y, Peng F, McGrail DJ, Patel S, Zhang X, Skoulidis F, Parra E, Dang M, Rodriguez S, Reuben A, Wistuba I, Wang L, Heymach JV. Suppression of macrophage migration inhibitory factor (MIF) impairs tumor growth and overcomes immunotherapy resistance in KEAP1-deficient NSCLC tumors. Cancer Research 80(12):2113-2113, 2022. e-Pub 2022.
15. Zhang C, Reuben A, Frank M, Liu S, Xie Z, Yan L, Qiu Z, Hong H, Su J, Tu H, Yang X, Zhang X, Yang J, Zhou Q, Wu Y, Zhang J, Zhong W. Single-cell evaluation reveals innate immune arrested and lymphocytes shifting that promote development of preinvasive lung adenocarcinoma, 2022. e-Pub 2022.
16. Schmidt ST, Akhave N, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget M, McGrail DJ, Weissferdt A, Lin S, Lee Y, Vokes N, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow C, Heffernan TP, Negrao MV, Gibbons DL. Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small …. Molecular Cancer Therapeutics 20(12):P009-P009, 2021. e-Pub 2021.
17. Reuben A, Jiang P, Nie H, Cobo AG, Dang M, Yu Q, Meredith F, Blitz E, Hamdi H, Denning W, Nilsson M, Poteete A, Shen L, Wang Q, Guijarro I, Nichols K, Khairullah R, Zhang J, Skoulidis F, Wang J, Wang L, Heymach J. 914 Loss of LKB1 is associated with resistance to IFN-gamma and T cell killing in non-small cell lung cancer. Journal for Immunotherapy of Cancer 9(2):A960-A960, 2021. e-Pub 2021.
18. Frank M, Shah P, Forget MA, Federico L, Jiang P, Khairullah R, Wistuba I, Chow C, Long Y, Fujimoto J, Lin S, Maitra A, Negrao M, Mitchell K, Weissferdt A, Vaporciyan A, Cascone T, Roth J, Zhang J, Sepesi B, Gibbons D, Heymach J, Haymaker C, McGrail D, Bernatchez C, Reuben A. 174 Combined IL-2, agonistic CD3 and 4–1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. Journal for Immunotherapy of Cancer 9(2), 2021. e-Pub 2021.
19. Le X, Dang M, Hedge V, Jiang, B, Slay R, Xiao W, Akagi K, Fresquez J, Marcelo K, Luo Q, Sinha P, Yanamandra A, Bell D, Williams M, Cuentas EP, Goepfert R, Lai S, Gross N, Agrawal A, Reuben A, Myers J, Curran M, Sastry J, Wang L, Gillison M. 754 TIGIT-PVR is a key immune checkpoint and therapeutic target in HPV-positive head and neck squamous cell carcinomas. Journal for Immunotherapy of Cancer 9(2):A788-A788, 2021. e-Pub 2021.
20. Galan-Cobo A, Yu Q, Peng F, McGrail D, Zhang F, Zhang X, Parra E, Dang M, Rodriguez S, Reuben A, Wistuba I, Skoulidis F, Wang L Heymach J. 926 Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy. Journal for Immunotherapy of Cancer 9(2):A971-A971, 2021. e-Pub 2021.
21. Luo Q, Parra E, Negrao M, Akhave N, Bayley E, Mitchell K, Zhang J, Heymach J, Sepesi B, Wistuba I, Gibbons G, Reuben A. 46 Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC. Journal for Immunotherapy of Cancer 9(2):A53-A53, 2021. e-Pub 2021.
22. Schmidt S, Lee Y, Leung C, Federico L, Lin H, Weissferdt A, Pataer A, Dejima H, Francisco-Cruz A, Rojas F, Solis L, Parra E, Pradhan M, Guo H, William W, Reuben A, Kadara H, Wistuba I, Zhang J, Swisher S, Vaporciyan A, Negrao M, Bristow C, Heffernan T, Bernatchez C, Lee J, Heymach J, Sepesi B, Gibbons D, Haymaker C, Cascone, T. 962 Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer. Journal for Immunotherapy of Cancer 9(2), 2021. e-Pub 2021.
23. Lee Y, McGrail D, Tran H, Vasquez ME, Ramos C, Reuben A, Vaporciyan AA, Weissferdt A, Bernatchez C, Cascone T, Wistuba II, Zhang J, Heymach J, Negrao MV, Gibbons DL, Sepesi B, Haymaker CL. Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer. Cancer Research 81(13):1670-1670, 2021. e-Pub 2021.
24. Akhave N, Schmidt S, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Lin Y, Lee Y, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow CA, Negrao MV, Gibbons DL. Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in …. Cancer Research 81(13):619-619, 2021. e-Pub 2021.
25. Ostmeyer JL, Christley S, Reuben A, Zhang J, Cowell L. Controlling for Confounding Factors when Diagnosing Cancer from T Cell Receptor Repertoires. The Journal of Immunology 206(1):12.11-12.11, 2021. e-Pub 2021.
26. Frank M, Yu F, Reuben A, Peng M, Yang G, Chen X, Ji L, Li P, Xia X, Guan Y, Zhang J. Spatial analysis of the T-cell repertoire in non-small cell lung cancer reveals a clonality gradient from the tumor to the distal lung. Journal of Clinical Oncology 39(15):e20544-e20544, 2021. e-Pub 2021.
27. Tseng D, Chiou S, Yang X, Reuben A, Wilhelmy J, McSween A, Conley S, Sinha R, Nabet B, Wang C, Shrager JB, Berry MF, Backhus LM, Lui N, Wakelee HA, Neal JW, Zhang J, Garcia KC, Mackall C, Davis M. Discovery of a novel shared tumor antigen in human lung cancer. Journal of Clinical Oncology 38(15):3087-3087, 2020. e-Pub 2020.
28. Huang J, Zhao G, Peng Q, Ma J, Li P, Chang L, Guan Y, Reuben A, Xia X, Yi X, Zhang J, Chen Z. Genomic and immune intratumor heterogeneity in gastric linitis plastica. Journal of Clinical Oncology 38(15):e16518-e16518, 2020. e-Pub 2020.
29. Chiou S, Tseng D, Yang X, Reuben A, McSween A, Wilhelmy J, Wang C, Shrager J, Zhang J, Garcia KC, Mackall C, Davis MM. Abstract A26: Towards the identification of novel tumor antigens in human lung cancer. Cancer Immunology Research 8(3):A26-A26, 2020. e-Pub 2020.
30. Chiou S, Tseng D, Wang C, Reuben A, Yang X, Wilhelmy J, McSween A, Zhang J, Shrager J, Garcia KC, Davis M. Towards the identification of novel tumor antigens in human lung cancer. Cancer Immunology Research 8(3):44-45, 2020. e-Pub 2020.
31. Gao H, Kida K, Cohen EN, Alexander A, Lim B, Parker C, Tin A, Valero V, Tripathy D, Reuben A, Ueno NT, Reuben JM. Abstract P3-09-12: Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory …. Cancer Research 80(4):P3-09-12-P3-09-12, 2020. e-Pub 2020.
32. Gao H, Kida K, Cohen EN, Alexander A, Lim B, Parker C, Tin S, Valero V, Tripathy D, Reuben A, Ueno NT, Reuben JM. Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory breast cancer (mIBC …. Cancer Research 80(4), 2020. e-Pub 2020.
33. Prieto P, Qin S, Williams A, Han B, Jewell R, Jackson K, Chacon A, Englerth E, Belt B, Micevic G, Linehan D, Gerber S, Reuben A. Interferon-gamma mediated T cell exhaustion generates distinct tumor microenvironments in synchronous melanoma via PD-1/PD-L1 axis. Journal of Immunotherapy of Cancer 7, 2019. e-Pub 2019.
34. Paranal RM, Kantarjian HM, Reuben A, Kerros C, Koppikar P, Little L, Gumbs C, Short NJ, Cortes JE, Jabbour E, Molldrem JJ, Futreal PA, Issa GC. Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant. Blood 134(5186), 2019. e-Pub 2019.
35. Gaudreau P, Negrao M, Mitchell K, Corsini E, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra E, Li J, Behrens C, Correa A, Gomez D, Vaporciyan A, Weissferdt A, Tran H, Roarty E, Wistuba I, Reuben A, Haymaker C, Bernatchez C, Cascone T, Heymach J, Sepesi B, Zhang J, Gibbons D. P2. 04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC. Journal of Thoracic Oncology 14(10):S715, 2019. e-Pub 2019.
36. Chen R, Jin Y, Li J, Zhang J, Fujimoto J, Lee W, Hu X, Chen Y, Behrens C, Chow C, Parra E, Little L, Gumbs C, Song X, Roarty E, Gibbons D, Heymach J, Lee JJ, William W, Glisson B, Wistuba I, Futreal PA, Byers L, Reuben A, Chen M. OA15. 04 Genomic and TCR Intratumor Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival. Journal of Thoracic Oncology 14(10):S246-S247, 2019. e-Pub 2019.
37. Gaudreau P, Ajami N, Sepesi B, Karpinets T, Reuben A, Wong M, Parra E, Federico L, Gopalakrishnan V, Mitchell K, Negrao M, Spencer C, Vaporciyan A, Weissferdt A, Haymaker C, Tran H, Bernatchez C, Landry L, Roarty E, Cascone T, Heymach J, Zhang J, Wistuba I, Wargo J, Gibbons D. P1. 04-11 Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data. Journal of Thoracic Oncology 14(10):S443, 2019. e-Pub 2019.
38. Reuben A, Zhang J, Gittleman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic AK, Benzeno A, Vignali M, Wu XX, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach J, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal PA. MA11. 09 Increased Frequency of Bystander T Cells in the Lungs Is Associated With Recurrence in Localized Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 14(10):S293, 2019. e-Pub 2019.
39. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose D, Fujimoto J, Roy-Chowdhuri S, Solis L, Dejima H, Cuentas EP, Mino B, Ikeda N, Luthra R, Gibbons D, Lang F, Lee JJ, Huse J, Kadara H, Wistuba I. P1. 04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 14(10):S441, 2019. e-Pub 2019.
40. Tang C, Lee WC, Chang L, Tran H, Reuben A, Xia X, Swisher SG, Heymach J, Zhang J, Gomez D. Radiation induced changes in the circulating T-cell repertoire and circulating tumor DNA in oligometastatic NSCLC; translational correlatives from a mature randomized phase II …. International Journal of Radiation Oncology, Biology, Physics 105(1):S25, 2019. e-Pub 2019.
41. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis LM, Dejima H, Cuentas ER, Mino B, Abraham R, Ikeda N, Luthra R, Lee JJ, Humam K, Huse JT, Wistuba II. Characterization of the immune microenvironment in brain metastasis from non-small cell lung cancer. Cancer Research 79(13):2790-2790, 2019. e-Pub 2019.
42. Mitra A, Andrews MC, Roh W, De Macedo MP, Reuben A, Carapeto F, Wang F, Reddy SM, Wani K, Spencer C, Miller J, Schalck A, Little LD, Sakellariou-Thompson DA, Gumbs C, Hwu W, Bernatchez C, Zhang J, Hwu P, Navin N, Sharma P, Allison JP, Wargo J, Lazar AJ, Futreal PA. Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy. Cancer Research 79(13):3776-3776, 2019. e-Pub 2019.
43. Le X, Negrao MV, Reuben A, Lee W, Parra E, Li J, Karpinets T, Behrens C, Sepesi B, Vaporiciyan A, Roth J, Haymaker C, Roarty E, Zhang J, Bernatchez C, Zhang J, Wistuba I, Gibbons D, Heymach J. Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype. Cancer Research 79(13):5028-5028, 2019. e-Pub 2019.
44. Gopalakrishnan V, Andrews M, Chen W, Spencer C, Vence L, Reuben A, Cooper ZA, Prieto PA, Tetzlaff MT, Khan MAW, Lazar A, Hudgens CW, Haydu LE, Tawbi HA, Hwu P, Hwu W, Amaria RN, Burton EM, Woodman SE, Diab A, Patel SP, Glitza IC, Zhang J, Petrosini J, Jenq RR, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. Cancer Research 79(13):1493-1493, 2019. e-Pub 2019.
45. Negrao MV, Karpinets T, Li J, Reuben A, Haymaker C, Mitchell KG, Fujimoto J, Chow C, Parra ER, Federico L, Zhang J, Vaporciyan AA, Bernatchez C, Cascone T, Sepesi B, Wistuba II, Heymach JV, Zhang J, Gibbons DL, team I. Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling …. Cancer Research 79(13):1176-1176, 2019. e-Pub 2019.
46. Lee W, Gomez D, Zhang J, Reuben A, Jalali A, Roh W, Wu CC, Lu W, Chow C, Fujimoto J, Antonoff M, Moran C, Sulman E, Rao G, Swisher S, Heymach J, Wistuba II, Futreal A, Zhang J. Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer. Cancer Research 79(13):2741-2741, 2019. e-Pub 2019.
47. Hong L, Dibaj S, Negrao MN, Reuben A, Roarty E, Rinsurongkawong W, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Futreal PA, Wistuba II, Roth JA, Swisher S, Heymach J, Simon GR, Lee JJ, Zhang J. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 37(15):9017-9017, 2019. e-Pub 2019.
48. Mitchell KG, Diao L, Tran HT, Negrao MV, Karpinets T, Wang J, Cuentas ERP, Corsini EM, Reuben A, Federico L, Bernatchez C, Vaporciyan AA, Swisher S, Cascone T, Wistuba II, Heymach J, Zhang J, Gibbons DL, Haymaker CL, Sepesi B. Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer. Journal of Clinical Oncology 37(15):e14047-e14047, 2019. e-Pub 2019.
49. Reuben A, Zhang J, Lin HY, Little L, Gumbs C, Tran HT, Wang L, Haymaker CL, Mehran RJ, Rice DC, Walsh GL, Lee JJ, Wistuba II, Swisher S, Vaporciyan AA, Futreal A, Sepesi B, Heymach J, Gibbons DL, Cascone T, Group NS. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial). Journal of Clinical Oncology 37(15):8532-8532, 2019. e-Pub 2019.
50. Negrao M, Reuben A, Chen R, Sepesi B, Karpinets T, Parra E, Federico L, Vence L, Weissferdt A, Tran H, Vaporiciyan A, Haymaker C, Forget M, Vasquez M, Prado E, Chow C, Zhang J, Fujimoto J, Jack A Roth JA, Meraz IM, Roarty E, Landy LL, Wagner H, Bogatenkova E, Bernatchez C, Futreal PA, Wistuba I, Swisher S, Heymach J, Gibbons D. MA06. 02 Prospective immunogenomic profiling of non-small cell lung cancer: genomic and immune profiling updates from project ICON. Journal of Thoracic Oncology 13(10):S375, 2018. e-Pub 2018.
51. Negrao M, Reuben A, Robichaux J, Le X, Nilsson M, Elamin Y, Wu C, Zhang J, Landy LL, Roarty E, Rinsurongkawong W, Swisher S, Simon G, Futreal PA, Glisson B, Heymach J. P2. 04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 13(10):S733-S734, 2018. e-Pub 2018.
52. Roman J, Baker M, Reuben A, Hill N, Hudgens C, Tetzlaff M, Logemann, Brownell I. Spontaneous regression of Merkel cell carcinoma is associated with clonal T-cell expansion. Journal of the American Academy of Dermatology 79(3):AB268-AB268, 2018. e-Pub 2018.
53. Qin Y, Petaccia de Macedo M, Roszik J, Spencer CN, Reuben A, Carapeto F, Wargo JA, Lazar AJ, Patel SP. Systematic analysis of immune profiles in uveal melanoma primary and metastatic tumors. Investigative Ophthalmology & Visual Science 59(9):3179-3179, 2018. e-Pub 2018.
54. Mitra A, Roh W, Reuben A, Wargo J, Lazar A, Futreal PA. Multi-spatial whole-lesion molecular heterogeneity analyses of an immunotherapy-resistant metastatic melanoma. Cancer Research 78(13):2099-2099, 2018. e-Pub 2018.
55. Chen R, Fujimoto J, Reuben A, Ying L, Hu X, Chow C, Canales JR, Sun W, Hu J, Cuentas ERP, Behrens C, Wu C, Little L, Gumbs C, Wiesnoski D, Han G, Lee W, Scheet P, Kadara H, Antonoff M, Vaporciyan AA, Swisher S, Zhang J, Heymach J, Hong WK, Wistuba I, Futreal A, Su D, Zhang J. T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. Cancer Research 78(13):4686-4686, 2018. e-Pub 2018.
56. Baker M, Roman JW, Reuben A, Hill N, Hudgens CW, Tetzlaff M, Logemann NF, Brownwell I. Spontaneous regression of Merkel cell carcinoma is driven by adaptive immune activation and clonal T cell expansion. Cancer Research 78(13):4676-4676, 2018. e-Pub 2018.
57. Livingston JA, Beird H, Wu CC, Cao S, Advani SM, Ingram D, Wang W, Lazar AJ, Leung CH, Lin HY, Reuben A, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Gorlick RG, Lewis VO, Futreal A, Daw NC. Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity. Journal of Clinical Oncology, 2018. e-Pub 2018.
58. Mitra A, Roh W, Reuben A, Macedo M, Carapeto FCL, Gumbs C, Zhang J, Woodman SE, Hwu P, Hwu W, Lazar AJ, Wargo JA, Futreal PA. Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma. Journal of Clinical Oncology, 2018. e-Pub 2018.
59. Negrao MV, Reuben A, Robichaux JP, Le X, Nilsson MB, Wu C, Zhang J, Landry LC, Roarty E, Rinsurongkawong W, Swisher S, Simon GR, Futreal A, Glisson BS, Zhang J, Heymach J. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. Journal of Clinical Oncology, 2018. e-Pub 2018.
60. Kalaora S, Wolf Y, Reuben A, Rosenberg SA, Lotem M, Sahin U, Wargo J, Friedman N, Admon A, Samuels Y. 24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. ESMO Open 3:A11, 2018. e-Pub 2018.
61. Wu C, Beird H, Livingston JA, Cao S, Advani SM, Ingram D, Wang W, Lazar AJ, Reuben A, Zheng Y, Roszik J, Wang W, Gorlick RG, Benjamin RS, Patel S, Daw NC, Futreal A, Lewis VO. Genome and transcriptome profiling of relapsed and metastatic osteosarcoma. Journal of Clinical Oncology, 2018. e-Pub 2018.
62. Reuben A, Gittelman R, Zhang J, Quek K, Vence LM, Behrens C, Chen R, Fujimoto J, Chow C, Wu X, Allison JP, Sharma P, Zhang J, Lee JJ, Sepesi B, Gibbons DL, Heymach J, Futreal A, Wistuba II, Zhang J, Team I. Association of the T-cell receptor landscape with survival in non-small cell lung cancer. Journal of Clinical Oncology 36(5):140-140, 2018. e-Pub 2018.
63. Reddy SM, Reuben A, Jiang H, Roszik J, Tetzlaff MT, Reuben J, Wang L, Tsujikawa T, Barua S, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Abstract P3-05-08: Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response. Cancer Research 78(4):P3-05-08-P3-05-08, 2018. e-Pub 2018.
64. Reddy SM, Reuben A, Jiang H, Roszik J, Tetzlaff MT, Reuben J, Wang L, Tsujikawa T, Barua S, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response. Cancer Research 78(4), 2018. e-Pub 2018.
65. Wargo J, Andrews M, Duong C, Gopalakrishnan V, Iebba V, Chen W, Derosa L, Routy B, Ferrere G, Fluckiger A, Roberti M, Opolon P, Roh W, Spencer C, Curbelo IF, Vence L, Reuben A, Cooper Z, Prieto P, Khan MW, Lazar A, Tetzlaff M, Hudgens C, Gaudreau P, Nezi L, Raoult D, Haydu L, Tawbi H, Hwu P, Hwu W, Amaria R, Burton E, Woodman S, Diab A, Patel S, Glitza I, Zhang J, Ajami N, Petrosino J, Jenq R, Davies M, Gershenwald J, Sharma P, Allison J, Futreal A, Zitvogel L, Alou MT, Yonekura S, Cogdill A, Arora R, Little L, Gumbs C, Wani K, Callahan M, Adamow M, Postow M, Ariyan C, Gardner J, McQuade J, Wong M, Zhao L. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade, 2017. e-Pub 2017.
66. Reddy SM, Amaria RN, Spencer CN, Tetzlaff M, Reuben A, Andrews M, Wang L, Woodman S, Zhu H, Blando J, Vence L, Zhang S, Jiang H, Gopalakrishnan V, Hudgens C, Wani K, Tawbi H, Diab A, Glitza I, Patel S, Hwu WJ, Wong M, Hwu P, Cormier J, Lucci A, Royal R, Lee JE, Simpson L, Burton EM, Gershenwald JE, Ross M, Allison J, Sharma P, Davies M, Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma …. Journal for Immuno Therapy of Cancer 5, 2017. e-Pub 2017.
67. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, Lee W, Li J, Wu X, Ye Y, Eterovic A, Little L, Gumbs C, Goplakarishnan V, Bernatchez C, Haymaker C, Forget Nm Federico L, Cascone T, Robins H, Roarty E, Rodriguez J, Parr E, Wargo J, Allison J, Sharma P, Zhang J, Lee J, Sepesi B, Swisher S, Gibbons D, Heymach J, Futreal A, Wistuba I, Zhang J. Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers, paired normal lung and peripheral blood mononuclear cells. Journal for Immunotherapy of Cancer 5, 2017. e-Pub 2017.
68. Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Miles A, Karpinets T, Vicente D, Prieto P, Hoffman K, Wei S, Cogdill A, Sanchez ER, McAllister F, Wong M, Davies M, Lazar A Gershenwald J, Ajami N, Cooper Z, Petrosino J, Daniel-MacDougall C, Tetzlaff M, Allison J, Sharma P, Jenq R, Wargo J. Diversity and composition of the gut microbiome influences responses to anti-PD1-therapy through beneficial changes in innate and adaptive immunity. Journal for Immunotherapy of Cancer 5, 2017. e-Pub 2017.
69. Hu X, Fujimoto J, Ying L, Reuben A, Chen R, Chow C, Rodriguez-Canales J, Sun W, Hu J, Parra ER, Carmen B, Wu C, Mao X, Song X, Li J, Gumbs C, Swisher SG, Zhang J, Heymach J, Hong WK, Wistuba I, Futreal A, Su D. P2. 02-013 Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing. Journal of Thoracic Oncology 12(11):S2103, 2017. e-Pub 2017.
70. Hu X, Fujimoto J, Ying L, Reuben A, Chen R, Chow C, Rodriguez-Canales J, Sun W, Hu J, Parra ER, Carmen B, Wu C, Mao X, Song X, Li J, Gumbs C, Swisher SG, Zhang J, Heymach J, Hong WK, Wistuba I, Futreal A, Su D, Zhang J. Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing. Journal of Thoracic Oncology 12(11):S2102-S2102, 2017. e-Pub 2017.
71. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, Lee W, Wu C, Li J, Wu X, Ye Y, Eterovic A, Little L, Gumbs C, Bernatchez C, Haymaker C, Forget M, Federico L, Cascone T, Robins H, Roarty E, Rodriguez J, Parra E, Wargo J, Allison J, Sharma P, Lee J, Sepesi B, Swisher S, Gibbons D, Heymach J, Futreal A, Wistuba I. OA 13.05 Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers and paired normal lung tissues. Journal of Thoracic Oncology 12(11):S1780, 2017. e-Pub 2017.
72. Reuben A, Gittelman R, Zhang J, Wu C, Fujimoto J, Rodriguez-Canales J, Swisher S, Heymach JV, Robins H, Lee JJ, Futreal A, Wistuba II. TCR repertoire of lung cancer: an association with tumor molecular and clinicopathological features. Journal of Thoracic Oncology 12(8):S1539, 2017. e-Pub 2017.
73. Woodman SE, Prieto P, Andrews MC, Amaria RN, Tetzlaff M, Diab A, Patel SP, Wen-Jen H, Glitza I, Tawbi H, Hwu P, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton E, Zhao L, Grimm E, Reuben A, Spencer C, Oba J, Ross M, Gershenwald J, Davies M, Wargo JA. Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response. Cancer Research 77(13):CT156-CT156, 2017. e-Pub 2017.
74. Lee J, Vellano CP, Meredith G, Mckay-Fleisch J, Ross PM, Tetzlaff M, Reuben A, Hudgens C, Wargo J, Garber J, White A, Pan J, Krouse M, Pansalawatta M, Dennis L, Kharkia A, Piazza E, Mashadi-Hossein A, Boykin R, Elliott N, Filanoski B, Demirkan G, Warren S, Geiss G, Kim D, Beechem J, Mills GB. 3D Biology™ view of cancer: Simultaneous detection of somatic DNA mutations and expression profiling of genes and signaling proteins from melanoma tumor FFPE samples. Cancer Research 77(13):5563-5563, 2017. e-Pub 2017.
75. Tang C, Heymach JV, Reuben A, Tran H, Welsh J, Wargo J, Liao Z, Tsao A, Prado E, Swisher S, Zhang J, Gomez D. Correlative analysis of systemic markers from a randomized trial assessing local consolidative therapy for non-small cell lung cancer (NSCLC) patients with oligometastatic disease. Cancer Research 77(13):2774-2774, 2017. e-Pub 2017.
76. Gopalakrishnan V, Spencer C, Reuben A, Prieto P, Vicente D, Karpinets TV, Hudgens CW, Hutchinson DS, Tetzlaff M, Lazar A, Davies MA, Gershenwald JE, Jenq R, Hwu P, Sharma P, Allison J, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. Cancer Research 77(13):2672-2672, 2017. e-Pub 2017.
77. Reuben A, Tetzlaff MT, Spencer C, Ong G, Barker K, Prieto PA, Vellano C, Lee J, Hudgens C, McKean MA, Gopalakrishnan V, Sloane RS, Reddy S, Merritt C, Warren S, Beechem J, Davies M, Hwu P, Mills GB, Wargo JA. Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in …. Journal of Clinical Oncology 35(15):9575-9575, 2017. e-Pub 2017.
78. Lee W, Gomez DR, Zhang J, Jalali A, Roh W, Reuben A, Lu W, Chow C, Wu C, Fujimoto J, Antonoff M, Moran C, Sulman EP, Rao G, Swisher S, Heymach J, Wistuba II, Futreal A, Zhang J, Team OS. Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis. Journal of Clinical Oncology 35(15):8541-8541, 2017. e-Pub 2017.
79. Reddy SM, Wargo JA, Reuben A, Tetzlaff MT, Roszick J, Reuben JM, Woodward WA, Ueno NT, Krishnamurthy S, Mittendorf EA. Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer. Journal of Clinical Oncology 35(15):11501-11501, 2017. e-Pub 2017.
80. Wargo AJ, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu W, Glitza IC, Tawbi HA, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. Journal of Clinical Oncology 35(15):3008-3008, 2017. e-Pub 2017.
81. Reuben A, Gittelman R, Zhang J, Yusko E, Wu C, Emerson RO, Zhang J, Tipton C, Vignali M Fujimoto J, Rodriguez-Canales J, Swisher S, Heymach J, Robins H, Lee JJ, Futreal A, Wistuba II, Zhang J, Study Team NT. TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues. Journal of Clinical Oncology 35(15):11500-11500, 2017. e-Pub 2017.
82. Gopalakrishnan V, Spencer C, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, Hwu P, Sharma P, Allison JP, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. Journal of Clinical Oncology 35(7):2-2, 2017. e-Pub 2017.
83. Reddy SM, Wargo JA, Reuben A, Reuben J, Woodward W, Ueno N, Mittendorf EA, Krishnamurthy S. Abstract P3-16-01: Immune characterization of inflammatory breast cancer and correlation to pathological complete response. Cancer Research 77(4):P3-16-01-P3-16-01, 2017. e-Pub 2017.
84. Prieto PA, Amaria R, Reuben A, Gopalakrishnan V, Spencer C, Jiang H, Zhang J, Tetzlaff M, Lazar A Burton E, Woodman S, Hwu P, Hwu W, Patel S, Tawbi H, Davies D, Diab A, Glitza I, Bassett R, Cormier J, Gershenwald J, Lee JE, Lucci A, Royal R, Ross M, Wargo JA. Novel Neoadjuvant Targeted Therapy Trial with Dabrafenib plus Trametinib Yields High Response Rates and Improved Relapse-Free Survival Over Standard of Care (SOC) Therapy in …. Annals of Surgical Oncology 24:S7-S7, 2017. e-Pub 2017.
85. Chen G, McQuade JL Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jane-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszick J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu W, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sulliivan RJ, Kim KB, Davies MA. Clinical, molecular and immune analysis of dabrafenib and trametinib in metastatic melanoma patients that progressed on BRAF inhibitor monotherapy: a phase II clinical trial …. JAMA oncology 2(8):1056, 2016. e-Pub 2016.
86. Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, Chen W, Cheung H, Jiang H, Heymaker C, Petaccia De Macedo M, Gerber HR, Chen P, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, Roszik J, Hwu P, Woodman SE, Chin L, Davies MA, Amaria RN, Patel SP, Lazar AJ, Tetzlaff MT, Dwyer KC, Wistuba II, Sharma P, Allison JP, Zhang J, Futreal A, Cooper ZA, Wargo JA. Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy. Cancer Research 76(14):2392-2392, 2016. e-Pub 2016.
87. Reuben, A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen P, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget M, Gopalakrishnan V, Amaria R, Davies M, Bernatchez C, Roger E, Cuentas P, Rodriguez J, Tetzlaff M, Woodman S, Dwyer K, Sharma P, Allison J, Chin L, Futreal A, Cooper Z, Wargo J. Molecular and immune heterogeneity in synchronous melanoma metastases. Journal for ImmunoTherapy of Cancer 3(2):1-1, 2015. e-Pub 2015.
88. De Macedo M, Reuben A, Qin Y, Reddy S, Spencer C, Jiang H, Bernatchez C, Austin-Breneman J, Gopalakrishnan V, Guindani M, Gombos D, Esmaeli B, Grimm E, Chattopadhyay C, Oba J, Woodman S, Hwu P, Williams M, Tetzlaff M, Cooper Z, Wargo J, Lazar A, Patel S. Understanding the determinants of resistance to therapy in metastatic uveal melanoma. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
89. P-L C, Roh W, Reuben A, Spencer C, Jiang H, Lazar A, Davies M, Miller J, Wani K, Hwu P, Patel S, Woodman S, Glitza I, W-J H, Cooper Z, Allison J, Sharma P, Wistuba I, Blando J, Prieto V, Tetzlaff M, Amaria R, Futreal A, Chin L, Wargo J. Immune infiltrate in early on-treatment biopsies is highly predictive of response to immune checkpoint blockade. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
90. Cooper Z, Reuben A, Prieto P, Spencer C, Austin-Breneman J, Jiang H, P-L C, Haymaker C, Amaria R, Vence L, Frederick D, Sullivan R, Flaherty K, Gershenwald J, Prieto V, Davies M, Patel S, Glitza I, Diab A, W-J H, Hwu P, Tetzlaff M, Chin L, Dwyer K, Wargo J. Patterns of immune infiltrate differ at progression on targeted therapy versus immune checkpoint blockade for melanoma. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
91. McQuade J, Guo C, Panka D, Reuben A, Bassett R, Joon A, Lazar A, Tetzlaff M, Simpson L, Mouton R, Glitza I, Patel S, W-J H, Amaria R, Diab A, Hwu P, Wargo J, Sulllivan R, Kim K, Davies M. Phase II study of dabrafenib (D) and trametinib (T) following progression on BRAF inhibitor (BRAFi): clinical and molecular predictors of response. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
92. Austin-Breneman J, Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Roh W, Cao Y, Little L, Amaria R, Garber H, Gopalakrishnan V, P-L C, Haymaker C, Forget MA, Davies M, Bernatchez C, Tetzlaff M, Woodman S, Dwyer K, Chin L, Futreal A, Cooper Z, Wargo. Immune and molecular heterogeneity in synchronous melanoma metastases. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
93. Jiang H, Prieto P, Reuben A, Austin-Breneman J, Spencer C, Gershenwald J, Cormier J, Lee J, Royal R, Lucci A, Ross M, Griffin K, Amaria R, Cooper Z, Wargo J, Tetzlaff M. Treatment with neoadjuvant BRAF/MEK inhibitors yields high response rates in patients with resectable metastatic melanoma. Pigment Cell & Melanoma Research 28(6), 2015. e-Pub 2015.
94. Reuben A, Amaria RN, Haymaker C, Forget MA, Bernatchez C, P-L C, Tetzlaff M, Davies MA, Dwyer KC, Wargo JA, Cooper ZA. Abstract A62: Immune and T cell receptor heterogeneity in distinct tumors within individual melanoma patients. Cancer Immunology Research 3(10):A62-A62, 2015. e-Pub 2015.
95. Reuben A, Cooper ZA, Roh W, Cao Y, Austin-Breneman J, Jiang H, Amaria RN, P-L C, Tetzlaff MT, Chin L, Futreal A, Davies MA, Wargo JA. Inter-and intra-tumoral immune and genomic heterogeneity in patients with metastatic melanoma. Cancer Research 75(15):1301-1301, 2015. e-Pub 2015.
96. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu W, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, Davies MA. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular …. Journal of Clinical Oncology 33(15):e20051-e20051, 2015. e-Pub 2015.
97. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, W-J H, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. Journal of Clinical Oncology 33(15):e20097-e20097, 2015. e-Pub 2015.
98. Wargo JA, Lawrence DP, Cooper ZA, Frederick DT, Giobbie-Hurder A, Piris A, Rubin KM, Fadden R, Reuben A, Lee S, Flaherty, Sharpe A, Sullivan RJ. A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma. Journal of Clinical Oncology 33(15):e20074-e20074, 2015. e-Pub 2015.
99. Cooper ZA, Reuben A, Spencer C, Austin-Breneman J, Jiang H, Chen P-L Haymaker C, Amaria RN, Tetzlaff MT, Flaherty KT, Chin L, Dwyer KC, Wargo JA. Understanding responses to targeted therapy and immunotherapy in melanoma: Rationale for combination strategies. International Journal of Molecular Medicine 36:S104-S104, 2015. e-Pub 2015.
100. Cooper Z, Reuben A, Amaria R, P-L C, Haymaker C, Tetzlaff, M, Davies M, Flaherty K, Chin L, Dwyer K, Wargo J. Differential patterns of leukocyte infiltrate at progression on targeted therapy versus immunotherapy for melanoma. Pigment Cell & Melanoma Research 27(6), 2014. e-Pub 2014.
101. Reuben A, Santos MM, Lapointe R. THE HEREDITARY HEMOCHROMATOSIS PROTEIN HFE INHIBITS MHC I ANTIGEN PRESENTATION. American Journal of Hematology 88(5):E124-E125, 2013. e-Pub 2013.
102. Reuben A, Santos M, Lapointe R. MHC CLASS I ANTIGEN PRESENTATION: EFFECT OF HFE, A PROTEIN INVOLVED IN IRON METABOLISM: Poster# 22. American Journal of Hematology 86(9), 2011. e-Pub 2011.
103. Qian Y, Galan-Cobo A, Guijarro I, Dang M, Poteete A, Zhang F, Wang Q, Wang J, Parra ER, Skoulidis F, Wistuba I, Verma S, Merghoub T, Wolchok JD, K-K W, DeBerardinis RJ, Minna J, Wang L, Reuben A, Heymach J. MCT4-Dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-Deficient NSCLC, 2011. e-Pub 2011.
104. Feferman EB, Reuben A, Quinkhardt J, Omokoko T, Haymaker C, Creasy C, Carter BW, Cooper ZA, Lotem M, Shakhar G, Wargo JA, Admon A, Greenstein E, Reshef D, Tirosh I, Paktar S, Levy R, Qutob N, Golani O, Zhang J, Mao X, Song X, Ruppin E, Friedman N, Samuels Y, Quinkhardt TO, Bernatchez C, Forget MA, Greenberg P, Rosenberg SA, Sahin U. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma, 2011. e-Pub 2011.
105. Hwu W-J PS, Glitza C, Hwu P, Tawbi H, McQuade JL, Burton M, Grimm EA, Reuben A, Spencer C, Gershenwald JE, Davies M. Treatment with neoadjuvant+ adjuvant dabrafenib and trametinib (D+ T) is associated with improved relapse-free survival (RFS) versus standard of care (SOC) therapy in patients …, 2011. e-Pub 2011.

Patents

1. Wargo J, Gopalakrishnan V. Improving responses to immune checkpoint blockade therapy by enhancing the diversity and composition of the gut microbiome in patients with cancer. Patent Number: PCT/US17/53717.
2. A series of T-cell receptors (TCRs) targeting epidermal growth factor (EGFR) neoantigens in cancer. Patent Number: PCT/US2021/058025.
3. Enhancing Responses to PD-1 Based Immunotherapy Through Modulation Of the Gut Microbiome To Enrich Butyrate Production. Patent Number: PCT/US2017/053717.